Sanofi has a few Phase II and Phase III trial ongoing for Asthma and COPD.
![]()
It appears a lot is riding on their (only) flagship product, Dupixent for respiratory ailments. Resapp fits like a glove to aid in their research capabilities and bring their trial to endpoints at a much faster pace. In my opinion Sanofi collaboration with Resapp to develop a standalone App is not only for direct to Consumer model (to check for drug adherence and also screening) , but also to aid in R&D projects.
If you dig deeper, Sanofi's collaborated with Science 37 for virtual trials, instead of getting the trial subjects to the location, to trial in Real World setting. I won't be surprised if they integrate Resapp algo into Science 37 to conduct trials in home setting . This also adheres well with FDA's Real World Evidence ( RWE) programs where they look favorably into companies which can prove their drug is suitable in Real world setting.
I was reading somewhere the Dupixent is expected to bring revenue in Billions out of which 30% could be related to treat Respiratory conditions.
![]()
Above all based on my research and opinions formed based on that. Please DYOR
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Grants Option to Consumer Health Division of Sanofi
Ann: ResApp Grants Option to Consumer Health Division of Sanofi, page-257
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online